Myostatin Is a Quantifiable Biomarker for Monitoring Pharmaco-gene Therapy in Duchenne Muscular Dystrophy

Myostatin Is a Quantifiable Biomarker for Monitoring Pharmaco-gene Therapy in Duchenne Muscular Dystrophy

Recently, several promising treatments have emerged for neuromuscular disorders, highlighting the need for robust biomarkers for monitoring therapeutic efficacy and maintenance of the therapeutic effect. Several studies have proposed circulating and tissue biomarkers, but none of them has been valid...

Full description

Bibliographic Details
Main Authors: Virginie Mariot, Caroline Le Guiner, Inès Barthélémy, Marie Montus, Stéphane Blot, Silvia Torelli, Jennifer Morgan, Francesco Muntoni, Thomas Voit, Julie Dumonceaux
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:Molecular Therapy: Methods & Clinical Development
Subjects:
myostatin
biomarker
neuromuscular disorders
clinical trials
Duchenne muscular dystrophy (DMD)
GDF8
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050120301406

Internet

http://www.sciencedirect.com/science/article/pii/S2329050120301406

Similar Items